WARSAW, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer is scheduled to participate in a fireside chat at two upcoming investor conferences being held in New York, NY.
| Event: | Stifel 2024 Healthcare Conference |
| Format: | Fireside Chat |
| Date: | Tuesday, November 19, 2024 |
| Time: | 10:55 am ET |
| Event: | Piper Sandler 36th Annual Healthcare Conference |
| Format: | Fireside Chat |
| Date: | Tuesday, December 3, 2024 |
| Time: | 9:00 am ET |
An audio webcast of the discussion will be available online at the OrthoPediatrics’ investor relations website, http://ir.orthopediatrics.com. Additionally, a replay will be available after the event.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 70 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
415-937-5406
| Last Trade: | US$21.19 |
| Daily Change: | 0.33 1.58 |
| Daily Volume: | 239,630 |
| Market Cap: | US$513.220M |
May 07, 2025 May 07, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
